查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047036

子宮頸癌診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、最終用戶、地區和競爭對手分類，2021-2031年

Cervical Cancer Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球子宮頸癌診斷市場預計將從 2025 年的 85.5 億美元成長到 2031 年的 125.2 億美元，複合年成長率為 6.56%。

子宮頸癌診斷，包括子宮頸抹片檢查和HPV DNA檢測等，對於發現子宮頸癌前病變和惡性腫瘤至關重要。子宮頸癌發生率的上升以及政府強制篩檢計畫的推廣，是推動市場擴張的主要因素，也因此產生了對早期檢測服務的持續臨床需求。例如，預計到2025年，美國將新增約13,360例浸潤性子宮頸癌病例，凸顯了對有效診斷方案的迫切需求。然而，開發中國家普遍存在的醫療基礎設施不足和資源匱乏是阻礙市場成長的主要挑戰。在這些國家，先進分子診斷檢測的高成本限制了其普及，嚴重阻礙了先進篩檢方案的廣泛應用，並限制了整體市場覆蓋範圍和收入潛力。

市場概覽
預測期 2027-2031
市場規模：2025年 85.5億美元
市場規模：2031年 125.2億美元
複合年成長率：2026-2031年 6.56%
成長最快的細分市場 子宮頸抹片檢查
最大的市場 北美洲

市場促進因素

兩大關鍵因素正在從根本上重塑子宮頸癌市場：一是人工智慧驅動的子宮頸癌篩檢演算法的進步，二是政府主導的國家篩檢計畫的廣泛實施。人工智慧與細胞學技術的融合，透過自動識別癌前病變，提高了檢測準確性和工作流程效率，從而減少人為錯誤並提升檢查室檢測能力。例如，Hologic公司的Genius數位診斷系統已將假陰性率降低了28%。同時，旨在根除子宮頸癌的公共衛生舉措正在調動大量資源。在全球範圍內，提高疫苗接種率、加強篩檢和治療計畫的努力正在穩步推進。 2024年3月，各國政府及其合作夥伴透過世界衛生組織（世衛組織）承諾提供約6億美元的資金，確保對診斷的持續需求和政策主導。羅氏等公司計畫在2025年對2,650萬名女性進行子宮頸癌風險篩檢。

市場挑戰

全球子宮頸癌診斷市場面臨的主要阻礙因素是開發中國家醫療基礎設施和資源的嚴重匱乏。儘管先進的分子檢測技術準確率很高，但其高昂的資本投入和營運成本阻礙了低收入地區的普及。因此，醫療機構被迫依賴效果較差但成本較低的方法，甚至完全放棄篩檢計畫。這種經濟差距實際上將大量人口排除在現代診斷服務之外，並限制了市場收入，使製造商難以進入這些市場。這些地區子宮頸癌負擔的差異令人震驚；根據世界衛生組織（世衛組織）預測，到2025年，全球約94%的子宮頸癌死亡病例將發生在低收入和中等收入國家，這直接表明，資金和基礎設施的不足如何限制了診斷市場的覆蓋範圍和商業性擴充性。

市場趨勢

目前，兩大趨勢正在重塑子宮頸癌診斷市場：一是家用和自取樣HPV檢體採集試劑盒的普及，二是指南從根本上轉向將人類乳突病毒（HPV）檢測作為初篩篩檢。家用試劑盒的出現打破了傳統臨床檢測的壁壘，徹底改變了市場准入方式；同時，監管部門的核准也擴大了非侵入性檢測的選擇範圍。例如，BD公司2024年5月的一項調查發現，56%的美國女性對陰道自取樣檢測感到滿意。同時，醫療機構正在更新診療方案，優先採用分子HPV檢測。分子HPV檢測在檢測癌前病變方面比子宮頸抹片檢查具有更高的靈敏度，促使實驗室轉向分子檢測平台。美國預防服務工作小組（USPSTF）等機構的建議進一步鞏固了這一轉變。 USPSTF於2024年12月建議，30至65歲的女性應每五年進行一次HPV篩檢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球子宮頸癌診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 檢查類型（子宮頸抹片檢查、HPV檢測、陰道鏡檢查、子宮頸切片檢查、膀胱鏡檢查）
    • 依最終使用者（醫院/診所、診斷檢測機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美子宮頸癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲子宮頸癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區子宮頸癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲子宮頸癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲子宮頸癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球子宮頸癌診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20916

The Global Cervical Cancer Diagnostic Market is projected to grow from USD 8.55 Billion in 2025 to USD 12.52 Billion by 2031, exhibiting a 6.56% CAGR. Cervical cancer diagnostics, encompassing tests like Pap smears and HPV DNA testing, are vital for detecting precancerous lesions and malignancies in the uterine cervix. This market's expansion is primarily fueled by the rising prevalence of cervical cancer and the increasing implementation of government-mandated screening programs, which create a consistent clinical demand for early detection services. For instance, an estimated 13,360 new cases of invasive cervical cancer are anticipated in the United States in 2025, highlighting the critical need for effective diagnostic solutions. A significant challenge, however, impeding market growth is the inadequate healthcare infrastructure and limited financial resources prevalent in developing nations, where the high costs of advanced molecular diagnostic tests restrict their adoption, thereby creating a substantial barrier to widespread advanced screening protocols and limiting the market's overall reach and revenue potential.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.55 Billion
Market Size 2031USD 12.52 Billion
CAGR 2026-20316.56%
Fastest Growing SegmentPap testing
Largest MarketNorth America

Market Driver

The market is fundamentally being reshaped by two key drivers: the advancement of AI-assisted cervical screening algorithms and the widespread implementation of government-mandated national screening programs. AI integration into cytology enhances test accuracy and workflow efficiency by automating the identification of pre-cancerous lesions, thereby reducing human error and increasing laboratory throughput, as exemplified by Hologic, Inc.'s Genius Digital Diagnostics System demonstrating a 28% reduction in false negatives. Simultaneously, public health initiatives aimed at cervical cancer elimination are mobilizing substantial resources, with global commitments like the nearly US$600 million pledged by governments and partners through the World Health Organization in March 2024, to expand vaccine coverage and strengthen screening and treatment programs, ensuring a sustained and policy-driven demand for diagnostic volume, with companies like Roche screening 26.5 million women for cervical cancer risk in 2025.

Market Challenge

A primary restraint on the global cervical cancer diagnostic market is the significant lack of healthcare infrastructure and financial resources in developing nations. The high capital and operational costs associated with advanced molecular tests, despite their accuracy, prevent their adoption in lower-income regions, forcing healthcare providers to rely on less effective, low-cost methods or to forgo screening programs entirely. This economic disparity creates a ceiling for market revenue by effectively excluding a vast demographic from modern diagnostic services and making it challenging for manufacturers to penetrate these markets. The disproportionate burden of the disease in these areas is stark, with the World Health Organization reporting that approximately 94% of global cervical cancer deaths in 2025 occurred in low- and middle-income countries, directly illustrating how financial and infrastructural deficits limit the diagnostic market's reach and commercial scalability.

Market Trends

Two prominent trends are currently reshaping the cervical cancer diagnostic market: the proliferation of at-home and self-sampling HPV collection kits and a fundamental shift towards Human Papillomavirus primary screening guidelines. At-home kits are revolutionizing market access by removing traditional barriers to clinical exams, with regulatory approvals expanding diagnostic reach to populations seeking non-invasive options; for instance, a BD survey in May 2024 found 56% of US women comfortable with self-collected vaginal tests. Concurrently, healthcare authorities are updating protocols to prioritize molecular HPV testing over Pap smears due to its superior sensitivity in identifying precancerous lesions, compelling laboratories to upgrade to molecular platforms. This transition is solidified by recommendations from bodies like the U.S. Preventive Services Task Force, which in December 2024 advised primary HPV screening every five years for women aged 30 to 65.

Key Market Players

  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Becton Dickinson and Company
  • Hologic Inc
  • CooperSurgical Inc
  • Siemens Healthineers AG
  • Quigan NV
  • F. Hoffmann-La Roche Ltd
  • Oncgnostics GmbH
  • Quest Diagnostics Inc.

Report Scope

In this report, the Global Cervical Cancer Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Cancer Diagnostic Market, By Test Type

  • Pap testing
  • HPV testing
  • Colposcopy
  • Cervical biopsies
  • Cystoscopy

Cervical Cancer Diagnostic Market, By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Cervical Cancer Diagnostic Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Cancer Diagnostic Market.

Available Customizations:

Global Cervical Cancer Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Cancer Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
    • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cervical Cancer Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cervical Cancer Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Cervical Cancer Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Cervical Cancer Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End User

7. Europe Cervical Cancer Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cervical Cancer Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Cervical Cancer Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Cervical Cancer Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Cervical Cancer Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Cervical Cancer Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Cervical Cancer Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cervical Cancer Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Cervical Cancer Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Cervical Cancer Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Cervical Cancer Diagnostic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Cervical Cancer Diagnostic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Cervical Cancer Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cervical Cancer Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Cervical Cancer Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Cervical Cancer Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End User

10. South America Cervical Cancer Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cervical Cancer Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Cervical Cancer Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Cervical Cancer Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cervical Cancer Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc
  • 15.3. Becton Dickinson and Company
  • 15.4. Hologic Inc
  • 15.5. CooperSurgical Inc
  • 15.6. Siemens Healthineers AG
  • 15.7. Quigan NV
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Oncgnostics GmbH
  • 15.10. Quest Diagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer